Overview
The production of human relaxin, specifically H2 and H3 forms of the relaxin protein, represents a significant achievement in genetic engineering. This review examines the various production methods utilizing both prokaryotic cells (such as bacteria) and eukaryotic systems, highlighting the challenges and innovations in creating biologically active recombinant human relaxin for therapeutic applications.
Prokaryotic Production Systems
E. coli Expression
Recombinant human relaxin (H2) has been successfully produced in E. coli, though this approach presents unique challenges. The produced protein often forms insoluble inclusion bodies, necessitating specialized purification and refolding processes.
The production process requires:
- Cell lysis to release the protein
- Denaturation of the inclusion bodies
- Complex and expensive in vitro refolding and reduction steps
- Careful processing to obtain biologically active, properly folded protein with two disulfide-linked chains
Despite these challenges, E. coli enables efficient production, with documented methods yielding approximately 2–3 mg of active human relaxin-3 per liter of culture broth.
Yeast Expression Systems
Pichia pastoris yeast has emerged as an alternative expression system, offering advantages in protein secretion. This system is frequently used for high-level production of active pro-relaxin, though it still faces challenges with protein precipitation into inclusion bodies.
Mammalian Cell-Based Production
While E. coli has been utilized for recombinant production, the complex and expensive refolding steps required have made mammalian cell systems increasingly attractive for producing correctly folded proteins. Mammalian systems leverage the body’s natural cellular machinery to produce properly processed relaxin.
Natural Production Sites
In mammals, relaxin is naturally produced in several tissues:
- Corpus luteum: Large luteal cells predominantly produce relaxin H2 during pregnancy
- Reproductive tissues: Endometrium, decidua, and placental trophoblast cells synthesize relaxin during pregnancy
- Male tissues: The prostate produces relaxin in males
Production Mechanism
Relaxin is synthesized as a preprohormone, which undergoes post-translational proteolytic cleavage of its signal peptide and C-domain to form the mature A-B heterodimer linked by disulfide bonds. This natural processing mechanism is preserved in mammalian cell expression systems.
Recombinant Expression Systems
Recombinant human relaxin (rhRLN) is produced in engineered cells for therapeutic studies, often targeting cardiovascular and fibrotic diseases. Several cell lines have proven effective:
- HEK293 Cells: Widely used for expression, with studies demonstrating that conditioned medium from transfected HEK293 cells can inhibit fibrotic markers
- AtT20 Cells: Employed for the production of recombinant human relaxin 3
- THP-1 Cell Line: Human monocytic cells used in cell-based assays to measure biological activity, such as cAMP production, of produced relaxin
Therapeutic Potential and Applications
Due to its role in collagen remodeling and its anti-inflammatory, anti-ischemic, and vascular effects, cell-based systems are vital for producing recombinant relaxin. Current research focuses on several therapeutic applications:
- Treatment of acute heart failure
- Management of fibrotic diseases
- Cardiovascular disease interventions
- Anti-inflammatory therapeutic strategies
Human Prorelaxin Patent Innovation
Genentech Patent
A landmark patent (EP JP AU NZ AU612594B2) was filed by Cornelia Maxine Gorman at Genentech, Inc., representing a significant milestone in relaxin production technology.
Patent Details:
- Priority Date: September 12, 1986
- Filed: September 11, 1987
- Granted: July 18, 1991
- Published: July 18, 1991
Patent Claims
The patent covers two key innovations:
1. Human preprorelaxin produced by recombinant cells: The patent claims human preprorelaxin that is essentially free of other naturally occurring human proteins, representing a purification breakthrough.
2. Transformation method: A method comprising transforming a eukaryotic host cell with an expression vector comprising nucleic acid encoding human prorelaxin under the control of transcriptional regulatory elements.
Key Contributors
Analysis of related patents reveals the top contributors to relaxin innovation:
- Genentech, Inc. (55.5% of related patents)
- Cornelia M. Gorman (33.3% of related patents)
- Debyra J. Groskreutz (22.2% of related patents)
Future Directions
The field of relaxin production and therapeutic application continues to evolve, with several promising directions:
- Optimization of mammalian expression systems to improve yield and reduce production costs
- Development of novel purification strategies to eliminate complex refolding steps
- Expansion of therapeutic applications beyond cardiovascular and fibrotic diseases
- Investigation of tissue-specific delivery mechanisms for enhanced therapeutic efficacy
- Clinical translation of recombinant relaxin therapies for broader patient populations
Conclusion
The innovation in relaxin production represents a convergence of genetic engineering, protein biochemistry, and therapeutic development. From the early challenges of bacterial expression systems to the sophisticated mammalian cell platforms available today, the field has made remarkable progress. The foundational work by researchers at Genentech, particularly the pioneering contributions of Cornelia M. Gorman and colleagues, established the technological framework that continues to drive therapeutic innovation in cardiovascular and fibrotic disease treatment.
As production methods continue to improve and our understanding of relaxin’s biological mechanisms deepens, the therapeutic potential of this remarkable protein continues to expand, offering hope for patients with conditions ranging from acute heart failure to systemic fibrosis.